This study explores the development of a dual-function airway stent (PAGL) incorporating anlotinib hydrochloride and silver nanoparticles using electrospinning technology to address tracheal in-stent restenosis (TISR). The PAGL stent combines anti-inflammatory and anti-angiogenic properties to modulate the tracheal microenvironment, reduce granulation tissue formation, and prevent restenosis.
Key findings:
PAGL exhibited hydrophobic surface properties, exceptional mechanical strength, and controlled drug release.
Effectively eradicated methicillin-resistant Staphylococcus aureus (MRSA) and suppressed inflammatory responses.
Significantly reduced angiogenesis and excessive fibroblast activation in human umbilical vein endothelial cells and lung fibroblasts.
Implantation in rabbits demonstrated inhibition of bacterial infection, reduced inflammation, and downregulation of fibrosis-related genes.
RNA sequencing confirmed suppression of pathways involved in fibrosis, intimal hyperplasia, and cell migration.
This study presents a novel airway stent with potential clinical applications for managing tracheal stenosis by targeting angiogenesis and inflammation.
Photo Credit: Canva